CME in Minutes: Education in Oncology & Hematology

Apr 05 2024 1

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

RSS feed Share

Copy RSS

Subscribe on Podcast Addict

Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer

Apr 05 2024 13 mins

Please visit answersincme.com/DDF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in advanced gastric cancer discuss the rationale for testing for HER2 status in patients with advanced gastric cancer and how to optimize care based on the latest clinical evidence. Upon completion of this activity,

Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients

Apr 05 2024 12 mins

Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon complet

Peter Lio, MD - AI in Healthcare: A Primer for the Practicing Clinician

Apr 05 2024 14 mins

Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients

Aditya Bardia, MD - Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer

Mar 29 2024 20 mins

Please visit answersincme.com/GTJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses endocrine receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Upon completion of this activity, participants should be better able to:

Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males

Mar 29 2024 15 mins

Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for va

Laura Spring, MD - The Patient-Clinician Alliance to Enhance Care for Patients With Metastatic Breast Cancer on Antibody-Drug Conjugates

Mar 25 2024 15 mins

Please visit answersincme.com/MVB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology and a patient advocate discuss strategies to optimize care for patients with metastatic breast cancer using antibody-drug conjugates. Upon completion of this activity, participants should be better able to:

Heather Wakelee, MD - Stepping Up Clinical Outcomes for Resectable NSCLC: Examining the Role of Neoadjuvant Plus Adjuvant Immunotherapy Regimens

Mar 14 2024 14 mins

Please visit answersincme.com/TAR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the integration of perioperative immunotherapy-based regimens for the treatment of resectable non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better

Sue S. Yom, MD, PhD - Latest Updates in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Clinical Potential of Inhibitor of Apoptosis Protein (IAP) Antagonists to Change the Treatment Landscape

Mar 08 2024 14 mins

Please visit answersincme.com/PQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in squamous cell carcinoma of the head and neck (SCCHN) discusses the clinical potential of antagonists of inhibitor of apoptosis proteins (IAPs) for unresected, locally advanced SCCHN. Upon completion of this activity

Steven M. Horwitz, MD - Advancing The Treatment Paradigm in Relapsed/Refractory B- and T-Cell Lymphoma: The Evolving Role of EZH1/2 Pathway Inhibitors

Mar 06 2024 14 mins

Please visit answersincme.com/HRM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cancerous lymphoma discusses EZH2 and EZH1 inhibitors for the management of relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas. Upon completion of this activity, participants should be better able to: De

Stephen M. Ansell, MD, PhD / Caron Jacobson, MD, MMSc - Navigating a New Treatment Algorithm for Patients With Relapsed/Refractory Follicular Lymphoma: Where Do CD20 x CD3 Bispecific Antibodies Fit In?

Feb 26 2024 16 mins

Please visit answersincme.com/XHR860 to participate, download slides and supporting materials, complete the post test, and obtain credit.In this activity, experts in follicular lymphoma discuss the integration of bispecific antibodies into the treatment of relapsing/refractory follicular lymphoma. Upon completion of this activity, participants should be better able to: Review the c

More Episodes